Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Psoriatic Arthritis-Pipeline Review, H1 2015

Psoriatic Arthritis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Psoriatic Arthritis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Psoriatic Arthritis-Pipeline Review, H1 2015', provides an overview of the Psoriatic Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Psoriatic Arthritis Overview 8

Therapeutics Development 9

Pipeline Products for Psoriatic Arthritis-Overview 9

Pipeline Products for Psoriatic Arthritis-Comparative Analysis 10

Psoriatic Arthritis-Therapeutics under Development by Companies 11

Psoriatic Arthritis-Therapeutics under Investigation by Universities/Institutes 15

Psoriatic Arthritis-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Psoriatic Arthritis-Products under Development by Companies 20

Psoriatic Arthritis-Products under Investigation by Universities/Institutes 23

Psoriatic Arthritis-Companies Involved in Therapeutics Development 24

AbbVie Inc. 24

AbGenomics International, Inc. 25

Alder Biopharmaceuticals Inc. 26

Amgen Inc. 27

Avesthagen Limited 28

Biocon Limited 29

Bristol-Myers Squibb Company 30

Celgene Corporation 31

Celltrion, Inc. 32

Coherus BioSciences, Inc. 33

Covagen AG 34

Eli Lilly and Company 35

Epirus Biopharmaceuticals, Inc. 36

Genor BioPharma Co., Ltd. 37

Inbiopro Solutions Pvt. Ltd. 38

Innovent Biologics, Inc. 39

Johnson & Johnson 40

Kineta, Inc. 41

Mabion SA 42

Momenta Pharmaceuticals, Inc. 43

Novartis AG 44

Oncobiologics, Inc. 45

Panacea Biotec Limited 46

Pfizer Inc. 47

Sandoz International GmbH 48

Swedish Orphan Biovitrum AB 49

Therapeutic Proteins International, LLC 50

UCB S.A. 51

Psoriatic Arthritis-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

abatacept (recombinant)-Drug Profile 61

AbGn-168H-Drug Profile 64

ABT-122-Drug Profile 66

adalimumab biosimilar-Drug Profile 68

adalimumab biosimilar-Drug Profile 69

adalimumab biosimilar-Drug Profile 70

adalimumab biosimilar-Drug Profile 71

adalimumab biosimilar-Drug Profile 72

adalimumab biosimilar-Drug Profile 73

adalimumab biosimilar-Drug Profile 74

adalimumab biosimilar-Drug Profile 75

adalimumab biosimilar-Drug Profile 76

anakinra (recombinant)-Drug Profile 77

apremilast-Drug Profile 78

bimekizumab-Drug Profile 81

brodalumab-Drug Profile 82

clazakizumab-Drug Profile 84

COVA-322-Drug Profile 86

dalazatide-Drug Profile 87

etanercept biosimilar-Drug Profile 89

etanercept biosimilar-Drug Profile 90

etanercept biosimilar-Drug Profile 91

etanercept biosimilar-Drug Profile 92

etanercept biosimilar-Drug Profile 93

etanercept biosimilar-Drug Profile 94

etanercept biosimilar-Drug Profile 95

etanercept biosimilar-Drug Profile 96

golimumab-Drug Profile 97

golimumab biosimilar-Drug Profile 100

guselkumab-Drug Profile 101

IBI-303-Drug Profile 104

IBPM-004AM-Drug Profile 105

IBPM-005IX-Drug Profile 106

infliximab biosimilar-Drug Profile 107

infliximab biosimilar-Drug Profile 109

infliximab biosimilar-Drug Profile 110

infliximab biosimilar-Drug Profile 111

infliximab biosimilar-Drug Profile 112

INV-17-Drug Profile 113

itolizumab-Drug Profile 114

ixekizumab-Drug Profile 116

Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis-Drug Profile 117

secukinumab-Drug Profile 118

tofacitinib-Drug Profile 122

Psoriatic Arthritis-Recent Pipeline Updates 126

Psoriatic Arthritis-Dormant Projects 176

Psoriatic Arthritis-Discontinued Products 177

Psoriatic Arthritis-Product Development Milestones 178

Featured News & Press Releases 178

Appendix 186

Methodology 186

Coverage 186

Secondary Research 186

Primary Research 186

Expert Panel Validation 186

Contact Us 186

Disclaimer 187

List of Tables

Number of Products under Development for Psoriatic Arthritis, H1 2015 12

Number of Products under Development for Psoriatic Arthritis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Psoriatic Arthritis-Pipeline by AbbVie Inc., H1 2015 27

Psoriatic Arthritis-Pipeline by AbGenomics International, Inc., H1 2015 28

Psoriatic Arthritis-Pipeline by Alder Biopharmaceuticals Inc., H1 2015 29

Psoriatic Arthritis-Pipeline by Amgen Inc., H1 2015 30

Psoriatic Arthritis-Pipeline by Avesthagen Limited, H1 2015 31

Psoriatic Arthritis-Pipeline by Biocon Limited, H1 2015 32

Psoriatic Arthritis-Pipeline by Bristol-Myers Squibb Company, H1 2015 33

Psoriatic Arthritis-Pipeline by Celgene Corporation, H1 2015 34

Psoriatic Arthritis-Pipeline by Celltrion, Inc., H1 2015 35

Psoriatic Arthritis-Pipeline by Coherus BioSciences, Inc., H1 2015 36

Psoriatic Arthritis-Pipeline by Covagen AG, H1 2015 37

Psoriatic Arthritis-Pipeline by Eli Lilly and Company, H1 2015 38

Psoriatic Arthritis-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 39

Psoriatic Arthritis-Pipeline by Genor BioPharma Co., Ltd., H1 2015 40

Psoriatic Arthritis-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 41

Psoriatic Arthritis-Pipeline by Innovent Biologics, Inc., H1 2015 42

Psoriatic Arthritis-Pipeline by Johnson & Johnson, H1 2015 43

Psoriatic Arthritis-Pipeline by Kineta, Inc., H1 2015 44

Psoriatic Arthritis-Pipeline by Mabion SA, H1 2015 45

Psoriatic Arthritis-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46

Psoriatic Arthritis-Pipeline by Novartis AG, H1 2015 47

Psoriatic Arthritis-Pipeline by Oncobiologics, Inc., H1 2015 48

Psoriatic Arthritis-Pipeline by Panacea Biotec Limited, H1 2015 49

Psoriatic Arthritis-Pipeline by Pfizer Inc., H1 2015 50

Psoriatic Arthritis-Pipeline by Sandoz International GmbH, H1 2015 51

Psoriatic Arthritis-Pipeline by Swedish Orphan Biovitrum AB, H1 2015 52

Psoriatic Arthritis-Pipeline by Therapeutic Proteins International, LLC, H1 2015 53

Psoriatic Arthritis-Pipeline by UCB S.A., H1 2015 54

Assessment by Monotherapy Products, H1 2015 55

Number of Products by Stage and Target, H1 2015 57

Number of Products by Stage and Mechanism of Action, H1 2015 59

Number of Products by Stage and Route of Administration, H1 2015 61

Number of Products by Stage and Molecule Type, H1 2015 63

Psoriatic Arthritis Therapeutics-Recent Pipeline Updates, H1 2015 129

Psoriatic Arthritis-Dormant Projects, H1 2015 179

Psoriatic Arthritis-Discontinued Products, H1 2015 180

List of Figures

Number of Products under Development for Psoriatic Arthritis, H1 2015 12

Number of Products under Development for Psoriatic Arthritis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 55

Number of Products by Top 10 Targets, H1 2015 56

Number of Products by Stage and Top 10 Targets, H1 2015 56

Number of Products by Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Top 10 Routes of Administration, H1 2015 60

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61

Number of Products by Top 10 Molecule Types, H1 2015 62

Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

AbGenomics International, Inc.

Alder Biopharmaceuticals Inc.

Amgen Inc.

Avesthagen Limited

Biocon Limited

Bristol-Myers Squibb Company

Celgene Corporation

Celltrion, Inc.

Coherus BioSciences, Inc.

Covagen AG

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Genor BioPharma Co., Ltd.

Inbiopro Solutions Pvt. Ltd.

Innovent Biologics, Inc.

Johnson & Johnson

Kineta, Inc.

Mabion SA

Momenta Pharmaceuticals, Inc.

Novartis AG

Oncobiologics, Inc.

Panacea Biotec Limited

Pfizer Inc.

Sandoz International GmbH

Swedish Orphan Biovitrum AB

Therapeutic Proteins International, LLC

UCB S.A.

Psoriatic Arthritis Therapeutic Products under Development, Key Players in Psoriatic Arthritis Therapeutics, Psoriatic Arthritis Pipeline Overview, Psoriatic Arthritis Pipeline, Psoriatic Arthritis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com